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Abstract: Despite significant advances in cancer diagnostics and therapeutics the majority of cancer
unfortunately remains incurable, which has led to continued research to better understand its
exceptionally diverse biology. As a result of genomic instability, cancer cells typically have elevated
proteotoxic stress. Recent appreciation of this functional link between the two secondary hallmarks
of cancer: aneuploidy (oxidative stress) and proteotoxic stress, has therefore led to the development
of new anticancer therapies targeting this emerging “Achilles heel” of malignancy. This review
highlights the importance of managing proteotoxic stress for cancer cell survival and provides an
overview of the integral role proteostasis pathways play in the maintenance of protein homeostasis.
We further review the efforts undertaken to exploit proteotoxic stress in multiple myeloma (as an
example of a hematologic malignancy) and triple negative breast cancer (as an example of a solid
tumor), and give examples of: (1) FDA-approved therapies in routine clinical use; and (2) promising
therapies currently in clinical trials. Finally, we provide new insights gleaned from the use of
emerging technologies to disrupt the protein secretory pathway and repurpose E3 ligases to achieve
targeted protein degradation.
Keywords: proteotoxic stress; chemoresistance; proteasome; unfolded protein response; autophagy;
multiple myeloma; triple negative breast cancer; protein quality control
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1. Introduction
1.1. Tight Regulation Over the Central Dogma of Molecular Biology is Essential for Cell Survival
The key to cell survival and function is the tight control over the central dogma of molecular
biology. This is the structured flow of genetic information from DNA → mRNA → protein
that underlies the dynamic processes in living cells. Due to the fact that protein homeostasis is
absolutely crucial to cell survival, it is tightly regulated at different stages of the DNA-mRNA-protein
pathway: (1) transcription (through epigenetic mechanisms), (2) RNA metabolism and processing,
(3) ribosomal protein synthesis, (4) protein folding (aided by chaperones), (5) protein translocation,
(6) protein assembly/disassembly, and (7) protein clearance [1,2]. Accumulation of misfolded proteins,
a consequence of disrupted protein homeostasis, initiates endoplasmic reticulum (ER) stress that, if not
promptly managed, leads to a global decline in cellular function and cell death [1].
1.2. Proteotoxic Stress: A Secondary Hallmark of Cancer
The protein synthesis process is intrinsically prone to errors. It has been estimated that up to 30%
of newly synthesized proteins are degraded by the proteasome within minutes of protein translation
in mammalian cells [3]. These rapidly degraded proteins are called defective ribosomal proteins
(DRiPs) or rapidly degraded polypeptides (RDPs), and if not removed, can dramatically increase basal
proteasome load and cell stress [4]. Cancer cells generally synthesize proteins (and therefore DRiPs)
more rapidly than normal cells due to increased cell division coupled to cell growth [5]. For example,
cancer cells that over-activate mTORC1, which promotes protein synthesis through inhibition of 4E-BPs
and activation of S6K1, become reliant on the immunoproteasome to prevent the accumulation of
misfolded proteins resulting from mTORC1 activation [6,7]. Such is the importance of proteostasis, that
mutations in RAS, PTEN, TSC1, and mTORC1 itself, enhance the formation of immunoproteasomes
as a mechanism to cope with increased proteotoxic stress resulting from downstream oncogenic
processes [7]. Besides DRiPs, genetic (exemplified by structural mutations) and environmental factors
such as hypoxia, oxidative stress, and nutrient deprivation are key activators of the integrated stress
response (ISR), a cytoprotective response to proteotoxic stress [4,8,9].
1.3. Endoplasmic Reticulum (ER) Stress is Closely Linked to Oxidative Stress in Cancer
Proteotoxicity is a key feature of both oxidative and reductive stress [10–12]. ER protein-folding
homeostasis can be disrupted by altered redox balance within the ER lumen which disrupts protein
folding to cause ER stress [13]. Accumulating evidence shows that ER stress signalling is elicited in
response to treatments that enhance the intracellular release of reactive oxidative species (ROS) [14–16].
On the other hand, oxidative protein folding (disulfide bond formation) in the ER, results in the release
of ROS as a by-product, which can then be used to activate a variety of transcription factors including
NF-κB, AP-1, p53, HIF-1α, PPAR-γ, β-catenin/Wnt, and Nrf2 to help cancer cells maintain their high
proliferation rate [17,18]. While moderate increases in ROS support tumorigenesis, excessive levels of
oxidative stress causes damage to cancer cells; a feature that can be exploited therapeutically using
ROS-modulating agents [19].
1.4. Aneuploidy Contributes to Proteotoxic Stress
Aneuploidy, which in turn is a manifestation of genomic instability, contributes to enhanced
and elevated proteotoxic stress in cancer cells [20–22]. Recent studies performed in aneuploid yeast
have shown that excessive protein production, secondary to extra chromosomes, disrupts proteostasis
resulting in growth inhibition [23,24]. In human cancer cell lines, polyploidy has been associated with
the induction of the unfolded protein response (UPR) and autophagy [25].
Perhaps the best example of the proteotoxic stress phenotype is multiple myeloma (MM), a type of
plasma cell dyscrasia typified by near universal aneuploidy (and genomic instability), and characterised
by high synthesis rates of immunoglobulins, and therefore DRiPs [26,27]. MM cells exhibit stigmata of
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ongoing proteotoxic stress with the accumulation of polyubiquitinated proteins, the baseline induction
of the UPR, and significant reliance on proteostasis pathways for survival [27–29].
2. Overview of the Protein Quality Control System
Cancer cells maintain the integrity of the proteome through an interconnected network of proteostasis
pathways (Figure 1). At its core is the ubiquitin proteasome system (UPS), which works together
with the macroautophagy (autophagy-lysosome) system and the aggresome pathway to regulate
protein clearance [20]. The unfolded protein response (UPR) is an adaptive response to ER stress
that, in addition to regulating ribosomal protein synthesis, is also able to recruit the other proteostasis
pathways (such as the aggresomal or macroautophagy pathways) to either maintain proteostasis or
induce apoptosis if ER stress remains unmitigated [30]. Upstream of the proteasome, the heat shock
chaperone protein system, which can be induced in response to proteotoxic stress, contributes to
protein homeostasis by regulating protein folding [31].
Cancers 2018, 10, x 4 of 21 
 
consensus is that depending on the type of cancer, a basal level of autophagy provides an alternative 
proteolytic pathway and might be essential for survival especially in times of proteotoxic stress [47]. 
However, persistent and uncontrolled proteotoxic stress induces autophagic cell death through the 
over-expression of Beclin-1 (an autophagy regulatory protein) [47,49]. This highlights a common 
theme that proteostasis is a delicate balance that needs to be struck through (1) precise regulation 
within each protein quality control pathway, and (2) tightly-controlled interactions between the 
different proteostasis pathways (Figure 1). 
 
Figure 1. Protein handling pathways in cancer cells. cancer cells have to cope with a large burden of 
misfolded proteins, which if not managed appropriately results in endoplasmic reticulum (ER) stress 
and eventual cell death. As such, cancer cells are highly dependent on a tightly regulated network of 
protein quality control pathways such as (A) the ubiquitin proteasome system (UPS), (B) 
macroautophagy, (C) aggresome formation, (D) heat shock response, and (E) the unfolded protein 
response. 
2.3. Aggresome Pathway 
Polyubiquitinated (misfolded) proteins that coalesce to form aggresomal particles are 
transported towards the microtubule organizing center (MTOC) in a histone deacetylase 6 (HDAC6)-
dependent fashion and sequestered into aggresomes that target these proteins for degradation by 
autophagy, or refolding by the heat-shock protein (HSP) chaperone system (Figure 1C) [50]. 
2.4. Heat-Shock Protein (HSP) Chaperone System 
As eluded to previously, misfolded proteins can undergo one of two fates: (1) protein clearance 
through the aforementioned pathways or (2) protein refolding with the help of HSP chaperones. 
Figure 1. rotei a li g at ays i cancer cells. cancer cells have to cope with a large burden
of misfol ed proteins, w ich if not managed appropriately results in endoplasmic reticulum (ER)
stress and eventual cell death. As such, cancer cells are highly dependent on a tightly r gulated
network of protein quality control pathway such as (A) the ubiquitin pr teasome system (UPS),
(B) macroautophagy, (C) aggresome formation, (D) heat shock respo se, and (E) the unfold d
protei r sponse.
Cancers 2019, 11, 66 4 of 21
2.1. Ubiquitin Proteasome System (UPS)
Protein degradation through the UPS begins with the polyubiquitination of targeted (misfolded)
proteins by a three-enzyme cascade involving E1 (activating), E2 (conjugating), and E3 (ligating)
enzymes (Figure 1A) [32]. Polyubiquitinated proteins are subsequently translocated to the 26S
proteasome; an ATP-dependent multi-catalytic complex comprising a 20S catalytic core flank on either
ends by 19S regulatory caps [33]. Polyubiquitinated proteins are recognized by the 19S regulatory
substrate and deubiquitinating enzymes (RPH11, UCH37, and USP14) within the 19S cap [34]. The
19S cap facilitates the removal of the polyubiquitin chain, which would otherwise sterically hinder
the translocation of misfolded proteins through the narrow pore formed by the 19S cap into the
catalytic core [34]. The 20S core contains three main catalytic subunits: the β1 (caspase-like activity),
β2 (trypsin-like activity), and β5 (chymotrypsin-like activity) subunits [35]. The proteasome inhibitors
(PIs) bortezomib, carfilzomib, ixazomib, and oprozomib largely target the β5 subunit while the
pan-proteasome inhibitor marizomib has been shown to inhibit all three β subunits [36–39].
De-ubiquitinating enzyme (DUB) inhibitors (P5091, B-AP15, and VLX1570), on the other hand,
prevent the removal of polyubiquitin chains, resulting in the accumulation of misfolded proteins
and apoptosis, without inhibiting the catalytic subunits of the proteasome [40–42]. DUB inhibitors
could potentially have clinical utility in cases of bortezomib resistance mediated by mutations in the
proteasomal catalytic subunits [43,44].
Recent research has identified the compensatory proteasome “bounce-back” response, mediated
by NRF1 activation as a potential mechanism of resistance to proteasome inhibition in cancer cells [45].
Nuclear factor erythroid-derived 2-related factor 1 (NRF1) is an ER-resident transcription factor of
the cap “n” collar basic leucine zipper family that is continually retro-translocated and degraded by
the proteasome [45]. When proteasome activity is inhibited, the transcription factor NRF1 (nuclear
factor erythroid derived 2-related factor 1) escapes degradation and is cleaved and activated by the
aspartyl protease DDI2 (DNA-damage inducible 1 homolog 2) [46]. Activation of NRF1 results in the
transcription of proteasome (PSM) genes followed by de novo proteasome formation [45]. In contrast
with NRF1 WT cells, NRF1 biallelic knockout cells lacked the ability to recover proteasome activity in
response to proteasome inhibition [45].
2.2. Macroautophagy (Autophagy-Lysosome System)
Macroautophagy is a lysosomal degradation pathway that plays an important role in proteostasis
through the sequestration and removal of misfolded proteins (Figure 1B) [47]. This affords cancer cells
the flexibility to tolerate stress, particularly when the other proteostasis pathways are overwhelmed.
Misfolded proteins are engulfed by autophagosomes and upon fusion with lysosomes, are degraded
by lysosomal hydrolases [48]. While the scientific community remains divided as to whether
macroautophagy plays a protective or deleterious role in cancer, the general consensus is that
depending on the type of cancer, a basal level of autophagy provides an alternative proteolytic pathway
and might be essential for survival especially in times of proteotoxic stress [47]. However, persistent
and uncontrolled proteotoxic stress induces autophagic cell death through the over-expression of
Beclin-1 (an autophagy regulatory protein) [47,49]. This highlights a common theme that proteostasis
is a delicate balance that needs to be struck through (1) precise regulation within each protein quality
control pathway, and (2) tightly-controlled interactions between the different proteostasis pathways
(Figure 1).
2.3. Aggresome Pathway
Polyubiquitinated (misfolded) proteins that coalesce to form aggresomal particles are transported
towards the microtubule organizing center (MTOC) in a histone deacetylase 6 (HDAC6)-dependent
fashion and sequestered into aggresomes that target these proteins for degradation by autophagy,
or refolding by the heat-shock protein (HSP) chaperone system (Figure 1C) [50].
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2.4. Heat-Shock Protein (HSP) Chaperone System
As eluded to previously, misfolded proteins can undergo one of two fates: (1) protein clearance
through the aforementioned pathways or (2) protein refolding with the help of HSP chaperones.
HSPs are a large family of chaperones that play an important role in protein folding, particularly
in the presence of hypoxia, and oxidative and thermal stress (Figure 1D) [51]. Compared to normal
cells, cancer is even more reliant on the HSP chaperone machinery for proliferation and survival
because (1) cancer oncoproteins are often misfolded, and (2) the high levels of DRiPs production [51].
The two most widely studied HSPs in cancer are HSP70 and HSP90, both of which have been found
to stabilize dominant-negative (inactivating) mutant p53, thereby allowing cancer cells to evade
anti-growth signals [52]. HSP70 and HSP27, on the other hand, are able to directly interact with
protein intermediates in apoptosis pathways, thereby inhibiting programmed cell death [52]. Recent
studies have also found that HSP90 protects telomeres from erosion, thereby contributing to the
limitless proliferation and avoidance of senescence in cancer cells [52]. Furthermore, HSPs have been
implicated in all aspects of the various hallmarks of cancer such as angiogenesis, tumor cell invasion
and metastasis, tumor progression, and drug resistance [52].
HSP90, is also involved in chaperone-mediated autophagy (CMA), a selective form of autophagy
involving the recognition of specific targeting motifs in substrates (by cytosolic chaperones) and
delivery to lysosomes [53]. Specifically, HSP90 interacts with the CMA substrate-chaperone complex
at the lysosomal membrane and pharmacologic inhibition of HSP90 reduces CMA activity [53].
Lastly, HSPs also play a key role in regulating the unfolded protein response. BiP/GRP78, a HSP70
superfamily protein is a major ER chaperone protein that serves as the master regulator of ER protein
quality control by controlling the activation of the ER-transmembrane signalling molecules [54,55].
Recently, there has been growing interest in developing inhibitors against heat shock factor 1
(HSF1), the “master regulator” of the heat shock response, in an attempt to avoid compensatory
upregulation of individual chaperones [56]. While the previous view was that HSF1’s main impact
on tumor biology occurs indirectly through the regulation of HSP90 and HSP70, recent research has
shown that HSF1 may play a more direct role in altering the transcriptome of cancer cells [57].
2.5. The Integrated Stress Response (ISR)
The ISR is a common adaptive pathway that is activated in response to a variety of stress signals;
both extrinsically (such as hypoxia, nutrient deprivation, viral infection), and intrinsically (such as ER
stress) [58–62]. Cellular stress signals activate four distinct serine/threonine protein kinases: GCN2
(nutrient deprivation), PKR (viral infection), HRI (heme deprivation), and PERK (ER stress) that
converge on the phosphorylation of eIF2α (the core of ISR) [9,63]. Phosphorylation of eIF2α results in
the global attenuation of Cap-dependent mRNA translation coupled with the preferential translation
of ISR-specific mRNAs such as ATF4 and the expression of ATF4 target genes that alleviate proteotoxic
stress [9]. As part of a negative feedback loop, GADD34, which is induced by the ISR, dephosphorylates
eIF2α to terminate the ISR and restore protein synthesis and cell normal cell function [64]. While the
other ISR regulators such as GCN2 and HRI have also been linked to cancer survival and proliferation,
this review will focus on the role that PERK and the unfolded protein response (UPR) play in response
to ER protein misfolding and proteotoxic stress [65,66].
2.6. Endoplasmic Stress and the Unfolded Protein Response (UPR)
Central to the protein quality control mechanism of the cell, is a process termed ER-associated
degradation (ERAD), by which improperly folded proteins are retained in the ER and delivered
for proteasome degradation after retro-translocation into the cytosol [30]. The cytosolic ATPase p97
(VCP/Cdc48) delivers ubiquitinated proteins from the ER to the proteasome by translating ATP
hydrolysis into mechanical force; thereby playing a crucial role in ERAD [67]. Due to the fact that
protein degradation is coupled via the UPS, to the dislocation of proteins from the ER into the cytosol
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(a key step of ERAD), any conditions blocking ER retro-translocation and/or the UPS may also result
in misfolded protein accumulation within the ER [68–70]. Therefore, misfolded proteins trigger the
UPR regardless of whether they accumulate within or outside the ER (such as in the nucleus or
cytosol) [71]. When the misfolded protein load within the ER exceeds the threshold of ERAD, the
resultant accumulation of misfolded proteins causes endoplasmic stress and induces the UPR through
the activation of the stress sensors, (1) activating transcription factor 6 (ATF6), (2) inositol-requiring
enzyme 1 (IRE1), and (3) protein kinase RNA-like ER kinase (PERK), which represent the three
branches of the UPR (Figure 1E) [30]. The three branches of the UPR operate in parallel as feedback
loops that mitigate ER stress. Activation of PERK (and downstream phosphorylation of eIF2α)
and IRE1 (and downstream splicing of XBP1 mRNA), regulates ER expansion and decreases global
protein synthesis to decrease the flux of proteins entering the ER [30]. ATF6 activation leads to the
upregulation of ER-resident chaperone proteins involved in protein folding (such as BiP, protein
disulphide isomerase, GRP94) to ultimately increase ER protein folding capacity [30]. On the other
hand, when homeostasis fails (due to prolonged and overwhelming stress), prolonged activation of
the PERK-ATF4 pathway activates the transcription factor C/EBP homologous protein (CHOP) which
triggers apoptosis, outlining the double-edged nature of the UPR [30].
Studies have shown that crosstalk exists between the UPS, autophagy, and the UPR [72–74].
Specifically, activation of the PERK-eIF2α pathway and IRE1 has been implicated in the activation of
autophagy with ATF4 and CHOP found to transcriptionally regulate multiple autophagy-related (ATG)
genes [75]. Furthermore, the cytoplasmic portion of IRE1 is known to bind TNF receptor-associated
factor 2 (TRAF2) which, through its kinase activity, couples ER stress to c-Jun N-terminal kinase (JNK)
activation [76]. Activation of JNK leads to Bcl-2 phosphorylation, allowing Beclin-1 dissociation and
activation of the Phosphoinositide-3-Kinase (PI3K) complex and autophagy [77].
Activation of the UPR has been implicated in bortezomib resistance. Specifically, IRE1α initiates
the splicing of X-box binding protein 1 (Xbp1) [78,79], which is an important transcription factor
involved in the terminal differentiation of B-lymphocytes to plasma cells and subsequent induction of
antibody secretion [80]. Indeed, mature MM cells that have higher Xbp1s expression and higher levels
of antibody secretion have been found to be more sensitive to bortezomib compared to immature
Xbp1s(-) MM cells arrested at the pre-plasmablast stage [81]. On the other hand, mutations resulting
in Xbp1 inactivation have been found in two treatment-refractory MM patients [81,82]. A likely
explanation for this is that terminal plasma cell differentiation results in (1) progressively impaired
proteasomal capacity, and (2) increased antibody secretion resulting in a proteasome workload-capacity
imbalance; thereby, sensitizing cells to apoptosis by proteasome inhibition [4,83].
3. Exploiting Proteotoxic Stress in Hematologic Malignancies: Multiple Myeloma
3.1. Proteasome Inhibitors (PIs)
Proteasome inhibition has emerged as an extremely effective targeted therapeutic strategy as it
exploits the unique biology of MM in that myeloma cells have to deal with large amounts of misfolded
proteins, and hence, high levels of proteotoxic stress due to extensive immunoglobulin synthesis
(Table 1) [84,85]. Since the first phase I bortezomib trials almost 15 years ago, proteasome inhibitors
(PIs) have become a mainstay of therapy, contributing substantially to the increase in overall survival
of patients diagnosed with myeloma over the years [86]. PIs in clinical use can be classified into three
groups: (1) boronates, (2) epoxyketones, and (3) γ-lactam-β-lactones (salinosporamide) based on their
chemical structure and active moiety. Bortezomib is the “first-in-class” boronic acid PI that reversibly
inhibits the chymotrypsin-like activity of the proteasome [87]. Bortezomib first received FDA approval
in 2003 and has since been seen as a major break-through in the treatment of MM [88]. A meta-analysis
of 16 studies involving 5626 patients with MM reported that bortezomib prolongs overall survival
(OS), progression free survival (PFS), and improves response rates in trials of bortezomib versus no
bortezomib with the same or different background therapy [89].
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Table 1. Therapies targeting protein handling pathways in multiple myeloma (MM).
Drug Class Drug Name Mechanism of Action Study Design Status
PI
Bortezomib
Proteasome inhibition;
Apoptosis via caspase 8/9;
UPR apoptotic response
Single use approval FDA approved
Carfilzomib Irreversible proteasome inhibition Single use approval; Combinationtreatment DEX and/or LEN FDA approved
Ixazomib Oral Proteasome inhibitor Combination treatment with LENand DEX FDA approved
Oprozomib Proteasome inhibition;Apoptosis via caspase 8/9 Single agent Phase IB/II
Marizomib
Pan-Proteasome inhibition;
Apoptosis via caspase 8/9;
UPR apoptotic response
Single agent Phase I
UPR Modulators
MKC-3946 Inhibition of XBP1 splicing by IRE1αendoribonuclease domain inhibition
Combination treatment with
bortezomib Preclinical
Nelfinavir
Activation of PERK apoptotic pathway;
Upregulation of CHOP; Inhibition of
AKT phosphorylation
Combination treatment with
bortezomib Preclinical
Combination treatment with
bortezomib in R/R and
progressive MM
Phase I
HDACi
Panobinostat
Broad spectrum inhibitor of HDAC
leading to aggresome disruption;
Apoptosis via caspase 8/9;
UPR apoptotic response
Combination treatment with
bortezomib and DEX (where 2 or
more treatment options have been
used prior)
FDA approved
ACY-1215
(Ricolinstat)
Selective inhibition of HDAC6 leading to
aggresome disruption;
Apoptosis via caspase 8/9;
UPR apoptotic response
Combination treatment
with bortezomib Preclinical
Combination treatment
with carfilzomib Preclinical
Combination treatment with LEN
and DEX Phase IB
Autophagy
Inhibitors
Hydroxy-
chloroquine
Inhibition of autophagy by increased
lysosomal pH
Combination treatment
with bortezomib R/R MM Phase 1
Combination treatment
with carfilzomib Preclinical
Bafilomycin A1 Inhibition of autophagy by prevention ofautophagosome/lysosome fusion
Combination treatment
with bortezomib Preclinical
HSP Inhibitors
NVP-HSP990
HSP90 inhibitor;
Disruption of AKT,
JAK/STAT pathways
Single agent Preclinical
TAS-116
HSP90 inhibitor
Induction of apoptosis
Disruption of AKT & ERK
Single agent;
Combination treatment
with bortezomib
Preclinical
Tanespimycin HSP90 inhibitorInduction UPR
Combination treatment
with bortezomib Phase I/II
Carfilzomib and oprozomib, on the other hand, are irreversible chymotrypsin-like, epoxyketone
PIs while ixazomib and delanzomibs are reversible third generation oral boronic acid PIs [87].
Carfilzomib obtained FDA approval on the strength of a phase 2 study, showing significant efficacy in
refractory/relapsed (RR) MM (overall response rate of 23.7% with median duration of response and
median overall survival of 7.8 and 15.6 months in patients who were refractory to bortezomib) [90].
In preclinical studies, oprozomib has demonstrated cytotoxicity in MM in combination with lenalidomide
and/or HDAC inhibitor molecules, as well as bone anabolic effects [91,92]. The salinosporamide
PI marizomib inhibits all three catalytic subunits of the proteasome and is currently in clinical
development in MM (NCT02103335).
3.2. Autophagy Inhibitors
Dual inhibition of autophagy and the UPS with hydroxychloroquine (HCQ) in combination with
bortezomib, has recently emerged as a potentially useful strategy for overcoming therapeutic resistance
to proteasome inhibition [93]. Specifically, a phase I clinical trial reported a very good partial response
(VGPR) rate of 14%, when HCQ was used in combination with bortezomib in refractory/relapsed MM
(RRMM) (Table 1) [93]. HCQ also demonstrates synergistic activity when used in combination with
Cancers 2019, 11, 66 8 of 21
carfilzomib [94]. Bafilomycin A1, an inhibitor of the late phase of autophagy, has also been reported to
potentiate the anti-MM activity of bortezomib by inducing irreparable ER stress [73].
3.3. Blocking the Aggresomal Pathway through HDAC6 Inhibition
Panobinostat is a broad-spectrum HDAC inhibitor (HDACi) that has been FDA approved for
use in refractory/relapsed MM (RRMM) in combination with bortezomib and dexamethasone based
on favorable clinical trial results demonstrating a 35% overall response rate (ORR) [95]. However,
non-selective HDAC inhibitors have a narrow therapeutic index, thereby prompting the development
of isoform-specific HDAC inhibitors such as ACY-1215, a HDAC6-selective inhibitor. By disrupting
aggresome formation, preclinical studies have shown that ACY-1215 synergizes with proteasome
inhibition (with bortezomib and carfilzomib) against MM cells [96,97]. A multicenter phase IB clinical
trial assessing the efficacy of ACY-1215 in combination with lenalidomide and dexamethasone in
RRMM reported an overall response rate (ORR) of 55% [98].
3.4. Heat Shock Protein 90 (HSP90) Inhibitors
HSP90 is the most well-studied heat shock protein in MM. HSP90 inhibitors in preclinical
development include NVP-HSP990 and TAS-116 [99,100]. TAS-116 in particular has shown promising
synergism with bortezomib treatment [100]. Clinically, a phase I/II trial of tanespimycin (HSP90
inhibitor) in combination with bortezomib used in the treatment of RRMM reported a 27% ORR [101].
However, further development of tanespimycin was halted due to patent expiry in 2014 which made it
hard to justify further financial investment in the drug [102].
3.5. Unfolded Protein Response (UPR) Modulators
Drugs such as tunicamycin, thapsigargin, and brefeldin A are ER stressors that lead to the induction
of the UPR. Despite good anti-MM activity and synergism with proteasome inhibitors in vitro, clinical
translation has been limited by anticipated toxicities based on in vivo studies [29,103–105]. More recent
efforts at targeting the UPR have led to the development of IRE1α endoribonuclease domain specific
inhibitors such as MKC-3946. By inhibiting Xbp1 splicing, MKC-3946 activates the UPR through
the PERK pathway resulting in eIF2α phosphorylation and increased ATF4 and CHOP expression;
thereby enhancing ER stress-mediated apoptosis induced by bortezomib [106]. It is worthwhile noting
that while the inhibition of Xbp1 splicing in terminally differentiated MM (plasma) cells triggers
apoptosis in MM cells, Xbp1 splicing is paradoxically also required for plasma cell maturity which
is a key determinant of PI sensitivity (mature plasma cells have greater proteasome workload and
are therefore more sensitive to PI) [81]. The HIV protease inhibitor nelfinavir has also been shown to
potentiate the anti-MM activity of bortezomib through the induction of the UPR and CHOP-dependent
apoptosis [107]. A phase II trial of nelfinavir and bortezomib reported an ORR of 30% in the dose
escalation cohort and an ORR of 50% in an exploratory extension cohort comprising patients with both
bortezomib-refractory and lenalidomide-resistant MM (SAKK 65/08) [108]. Finally, targeting ERAD
through pharmacological inhibition of p97 using Eayarestatin 1 and DBeQ has recently emerged as a
means to disrupt intracellular protein metabolism within MM cells [67]. Of note, dual inhibition of p97
and the proteasome induced significant apoptosis in both cell lines and patient-derived MM cells with
minor toxicity observed in untransformed, non-secretory control cells [67].
4. Exploiting Proteotoxic Stress in Solid Tumors: Triple Negative Breast Cancer (TNBC)
4.1. Proteasome Inhibition in TNBC
While proteasome inhibitors have shown significant clinical efficacy in multiple myeloma and
mantle-cell lymphoma treatment, their effect against solid tumors such as triple negative breast cancer
(TNBC) has been less than encouraging [88,109,110]. TNBC is an aggressive chemoresistant subtype of
breast cancer with a poor clinical outcome. It is characterised by lack of expression of the estrogen
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receptor and the progesterone receptor, and the lack of overexpression of human epidermal growth
factor receptor 2 (HER2). Treatments are limited and non-specific, due to its innately treatment-resistant
biology. A recent study has revealed that inhibition of both the β5 and β2 sites of the proteasome
sensitised triple negative breast cancer cell lines to bortezomib [111]. This suggests that a dual inhibitor
may enhance the clinical benefit of bortezomib in solid tumors. Moreover, bortezomib, engineered to
be contained in nanoparticles, has shown promise as a drug delivery system for TNBC by overcoming
its clinical limitations such as low water solubility [112]. Furthermore, the chemotherapeutic paclitaxel
has been shown to regulate the genes involved in the ubiquitin proteasome system in breast cancer.
Specifically, paclitaxel treatment resulted in an upregulation of proteasome genes and lead to an
accumulation of proteasome subunits alpha 4 and beta 1, 26S ATPases 2 and 6 and 26S non-ATPase
14. Moreover, proteasome inhibition with MG132 following paclitaxel treatment resulted in growth
inhibition and apoptosis [113].
Clinically, a phase I/II trial has shown that the combination of capecitabine and bortezomib
in anthracycline and taxane pre-treated metastatic breast cancer patients was well tolerated [114].
These studies suggest that a combination regime of paclitaxel with proteasome inhibitors is a potential
treatment strategy for breast cancer patients. Studies have also suggested that the combination of
lapatinib and proteasome inhibitors may be beneficial for patients with a diagnosis of TNBC [115].
Importantly, a case study of a patient with TNBC who had adverse side effects to standard treatment,
was reported to have an 11-month progression free survival following bortezomib treatment [116].
Additional in-vitro studies have shown that bortezomib induced significant apoptosis in three
TNBC cell lines: HCC-1937, MDA-MB-231, and MDA-MB-468 via the inhibition of CIP2A (cancerous
inhibitor of protein phosphatase 2A) [117]. Moreover, bortezomib demonstrated in-vivo cytotoxic
activity in HCC-1937 xenografted tumors [117]. Bortezomib is a known substrate of P-glycoprotein,
a multidrug efflux transporter that plays a role in resistance to proteasome inhibition by facilitating PIs
to be pumped out of cancer cells, and it has been demonstrated that inhibition of the P-glycoprotein
using verapamil sensitizes MDA-MB-231 TNBC cells to the proteasome inhibitors MG132, bortezomib
and carfilzomib [118–120]. Intriguingly, gene silencing studies using small interfering RNA (siRNA)
have shown that “basal-like” TNBC cells were dependent on genes implicated in the proteasome
(PSMA1, PSMA2, PSMB4) for survival as silencing of these genes resulted in ≤50% viability compared
to control siRNA-transfected cells [121]. Consistent with the siRNA screen, basal-like TNBC cells were
more sensitive to proteasome inhibitors than other breast cancer types [121], suggesting the potential
promise of using proteasome inhibitors as a treatment strategy for TNBC patients.
4.2. Cellular Senescence and Proteotoxic Stress: A Double-Edged Sword?
The concept that cells will only divide until they reach a limit of cell division or replicative induced
senescence was devised by Hayflick (1961) and is termed the “Hayflick limit” [122]. This process
of replicative induced senescence (RIS) occurs due to telomere shortening after every round of
cell division. Senescence can also be induced specifically in cancer cells which are exposed to
treatment “stressors” such as radiation therapy or chemotherapy. Ideally, chemotherapy induces
tumor cell death via apoptosis. Paradoxically, tumor cells can maintain viability in response to
chemotherapy, by undergoing alternative fates such as therapeutic-induced-senescence (TIS) [123].
Although senescent cells are metabolically active, they are also proliferatively incompetent [124].
Therefore, chemotherapies such as paclitaxel, which preferentially impact on dividing cells, are less
likely to induce apoptotic cell death [125]. Increased expression of p21, p16, and senescence associated
β-galactosidase (SA-β-Gal) activity are well-established markers of senescent cells [126,127]. Moreover,
senescent cells secrete the senescence associated secretory phenotype (SASP); a secretome known to
be associated with cancer promoting phenomenon such as chronic inflammation, angiogenesis, cell
proliferation and cell invasion [128]. In addition, the ubiquitin proteasome system has been implicated
in the selective degradation of proteins involved in the onset and/or maintenance of senescence in a
process known as senescence associated protein degradation (SAPD) [129].
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Endoplasmic reticulum (ER) stress can occur in the senescent phenotype resulting from the
misfolding of proteins. This leads to the activation of the unfolded protein response (UPR) to deal
with the resultant misfolded proteins and proteotoxicity. A recent study of the WI-38 model of
replicative senescence and stress induced senescence induced by hydrogen peroxide and copper sulfate
demonstrated an impairment in the chaperoning mechanisms of the ER and UPR activation [130].
Activation of the UPR may therefore represent a mechanism by which senescent cells can maintain
viability and cellular survival in a stressful environment [131]. Another study has shown that WI38
fibroblasts that entered senescence at about 40 cumulative population doublings, had a reduced
proteasome function evidenced by increased levels of both oxidised and ubiquitinated proteins, which
could be explained by reduced protein expression of the catalytic subunits of the 20S proteasome and
subunits of the 19S regulatory complex [132]. Intriguingly, partial inhibition of the proteasome with
MG132 or epoxomicin induced a senescence-like phenotype in early-passage WI38 cells, suggesting
that loss of proteasome function could be a cause rather than an effect of cellular senescence [132].
Taken together, these studies demonstrate that proteostasis plays a central role in both the induction of
cellular senescence and the maintenance of cell viability during senescence.
Exosomes are extracellular vesicles (EVs) that are ~50–150 nm in size. These vesicles are of
endocytic origin released into the extracellular space [133], and consist of cytoplasm enclosed with
a lipid bilayer [134,135]. EVs are released by multiple cell types and can be found in blood, urine,
serum and amniotic fluid [136]. Moreover, therapeutic-induced-senescent (TIS) TNBC cells release
significantly more extracellular vesicles (EVs) than control cells [123]. Irradiation induced senescent
prostate cancer cells also release more EVs than controls [137]. This suggests that increased EV release
could be a potential mechanism conducive to cell survival following cellular stress, in that cells can
potentially prevent proteotoxicity and maintain cell proteostasis through the removal of misfolded
proteins into the extracellular space using EVs [138,139].
5. A Look at What’s on the Horizon
5.1. Disrupting the Protein Secretory Pathway to Increase Proteotoxic Stress
The synthesis of secretory or membrane proteins begins at 80S ribosomes attached to the wall
of the rough endoplasmic reticulum (ER) [140]. Newly translated proteins made in the ER lumen or
membrane are encapsulated within transport vesicles and trafficked to the golgi apparatus where they
undergo modifications and folding before being transported to their final destination [140]. Secretory
proteins are stored in secretory vesicles juxtaposed to the cell surface membrane where they await
appropriate signals for exocytosis [140]. Exocytosis, the fusion of secretory vesicles with the plasma
membrane is regulated by intracellular calcium influx and SNARE protein activation [141].
Dual inhibition of protein secretion and degradation has recently emerged as a promising
treatment strategy for malignant cells with high protein load. Specifically, by “overloading” MM
cells with misfolded proteins, the combination of Sec 61 inhibitors (inhibitor of protein secretion)
and carfilzomib or bortezomib, disrupted proteostasis bringing about synergistic cell death [142].
A separate study exploring the use of verapamil (a calcium channel blocker) to interfere with IgG
secretion in MM cells, reported that verapamil increased the cytotoxic effect of bortezomib by increasing
the accumulation of polyubiquitinated proteins and ER stress signalling within MM cells [143]. Another
approach taken to enhance proteotoxic stress in MM cells involves dual inhibition of monoclonal
protein trafficking (through the inhibition of the isoprenoid biosynthetic pathway) and protein folding
(by targeting HSP90) [144]. Intracellular protein trapping coupled with impaired protein chaperone
function resulted in the accumulation of misfolded proteins and the induction of the ER stress, UPR,
and ultimately cellular apoptosis [144].
Another strategy to accelerate proteotoxic stress by targeting immunoglobulin secretion in MM
was recently explored by Zhou et al. [145]. In this study, a pool of siRNA targeting λ light chains was
used to inhibit λ light chain production, which resulted in decreased secretion of intact immunoglobulin
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G (IgG) λ antibodies (containing paired heavy and light chains) [145]. In the absence of light chains,
the accumulation of unstable (unpaired) immunoglobulin heavy chains within the ER resulted in the
activation of the terminal UPR and apoptosis [145].
5.2. Hijacking E3 Ligases for Specific Target Protein Degradation via the Ubiquitin Proteasome System
Targeted protein degradation using “degraders” has recently emerged as an attractive and promising
approach against currently undruggable (and druggable) targets. Degraders are heterobifunctional
small molecules, with two binding motifs separated by a linker that bind to an E3 ubiquitin ligase
on one site and a specific protein of interest (POI) on the other site [146]. By redirecting the E3 ligase,
degraders facilitate the polyubiquination and subsequent proteasome degradation of specific POIs.
The three emerging technologies currently in preclinical development are the (1) PROTAC (PROteolysis
Targeting Chimera), (2) Degronimid, and (3) TRIM21 systems [147,148].
5.2.1. PROTAC System
PROTACs are the most well studied degrader technology (Figure 2A). Previous generations of
PROTACs were designed to hijack various E3 ligases such as β-TRCP, MDM2 [149], CIAP [150], and
von Hippel-Lindau (VHL) [151]. However, these compounds were large and hydrophilic, which
affected cell permeability, had low affinity for their targets, and lacked optimal linker geometry [146].
Early PROTACs were therefore very limited in their potency, evidenced by their activity in the
low-micromolar range with only partial degradation of POIs [146]. Next-generation PROTACs, on
the other hand, are designed with much higher affinities and selectivity for the VHL E3 ligase with
due consideration paid to the attachment point, length, and geometry of the linker [146]. As a
proof-of-concept, next-gen PROTACs that were developed against serine-threonine kinase RIPK2 had
the ability to specifically reduce protein levels by >90% at nanomolar concentrations both in-vitro and
in-vivo [152].
5.2.2. Degronimids
In 2014, the discovery that the immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide
act as a bridge between the Cereblon E3 ubiquitin ligase and Ikaros/Aiolos to enhance ubiquitination
and subsequent proteasome degradation of the latter, brought fresh perspectives to the field of targeted
protein degradation [153,154]. By utilizing degronimids (modified IMiDs) to alter (hijack) the activity of
Cereblon E3 ubiquitin ligase, the UPS can be manipulated to achieve targeted degradation of proteins
within cells (Figure 2B). An example of a degronimid in preclinical development is the phthalimide
conjugate dBET1 which specifically and potently degrades BRD4 in human leukemic cells; resulting in
rapid and robust apoptosis both in-vitro and in-vivo [147].
The challenge in designing effective heterobifunctional degraders that bridge POIs to an E3
ubiquitin ligase is learning how to maximize both selectivity and potency by varying linker composition
and length [155]. This design process would have to be optimized for each individual POI, and would
require the up-front identification of a target-selective ligand [155]. To circumvent this, Nabet et al.
developed the degradation TAG (dTAG) system: a two-step process involving (1) CRISPR/Cas-9
mediated knock-in of an FKBP12F36V protein tag, next to the gene of interest, and (2) the addition of a
degrader that bridges the resultant FKBP12F36V fusion protein of interest to the Cereblon E3 ligase [155].
This single generalisable approach allows for the rapid degradation of allele-specific protein chimeras,
thereby serving as a powerful tool for target validation and biological investigation in the context of
drug discovery.
5.2.3. TRIM21 System
TRIM21 is an E3 ubiquitin ligase that recognizes antibody-bound pathogens by binding with
high affinity to the Fc domain of antibodies [156,157]. Clift et al. developed a three-step strategy to
repurpose TRIM21 to achieve targeted protein degradation: (1) introduction of exogenous TRIM21,
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(2) introduction of an antibody against the POI, and (3) TRIM21-mediated polyubiquination of
antibody-bound POI and subsequent degradation by the UPS (Figure 2C) [158]. Like the dTAG
system, TRIM21 represents a novel method for studying protein function with future therapeutic
potential, especially in cancers that are highly susceptible to proteasome overload.
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Figure 2. Hijacking the ubiquitin proteasome system (UPR) for targeted protein degradation. Targeted
protein degradation has recently emerged as an attractive and promising approach against currently
undruggable (and druggable) targets. (A) the PROteolysis Targeting Chimera (PROTAC) system:
PROTACs are heterobifunctional molecules that serves as a bridge by binding to an E3 ligase on one
side and to the protein of interest on the other, thereby facilitating polyubiquitination and proteasome
degradation of the protein of interest. (B) deronimids are specifically modified immunomodulatory
drugs (IMiDs) that recruit the Cereblon E3 ubiquitin ligase to the protein of interest to facilitate target
proteasome degradation. (C) TRIM21 is an E3 ubiquitin ligase that recognizes and polyubiquitinates
antibody-bound substrates by binding with high affinity to the Fc domain of antibodies.
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6. Conclusions
The modern oncology paradigm hinges on genomic characterisation of tumors to increase our
fundamental understanding of cancer biology, thereby facilitating the design of novel therapeutics
exploiting various cancer vulnerabilities such as “oncogene addiction”. While this ideal of precision
medicine is an elegant approach to targeting cancer, tumor heterogeneity makes targeting multiple
continually evolving clonal and genetic abnormalities with the right combination, at appropriate
times, and in the correct sequence highly challenging [159]. This is why targeting the consequences of
genomic instability, such as blocking proteotoxic stress responses in cancer constitutes an attractive
therapeutic strategy that is echoed by the success of proteasome inhibition in MM. In spite of this, most
patients inevitably develop clinical resistance to proteasome inhibitors, prompting the development
of novel therapies that could potentially synergise with PIs to target other pathways involved in
protein quality control in cancer cells. Importantly, preclinical and early clinical trials suggest the
potency of combinations, such as PIs with UPR modulators, PIs with HDAC6 inhibitors, and PIs with
autophagy inhibitors.
Particularly exciting developments in the space of triple negative breast cancer (TNBC) are reports
suggesting that proteasome inhibition may be an effective strategy for reversing chemotherapy-induced
senescence; a mechanism that TNBC cells use to maintain viability and cellular survival and acquire
cancer chemotherapy resistance. Phase I/II clinical trials provide early evidence supporting the use
of a combination regime of proteasome inhibitors with paclitaxel, capecitabine, or lapatinib in the
treatment of anthracycline and taxane pre-treated metastatic breast cancer patients.
Finally, by hijacking the ubiquitin proteasome system within cancer cells, emerging technologies
aimed at repurposing various E3 ubiquitin ligases towards targeted protein degradation offer a
powerful tool for target validation and biological investigation in the context of drug discovery.
In conclusion, our increasing understanding of the over-reliance of cancer cells on proteostasis
pathways has led to the ongoing development of various distinct therapeutic strategies with the
common goal of exacerbating proteotoxic stress to cause irreparable damage and cancer cell apoptosis.
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